Living Cell Technologies Ltd. (AU:1AI) has released an update.
Algorae Pharmaceuticals has successfully launched its AI platform, AlgoraeOS, which uses advanced neural networks to predict drug target synergies. In preclinical studies, their AI-116 drug candidate for dementia showed promising results, surpassing existing treatments. The company is also advancing trials for AI-168, targeting cardiovascular diseases, with results expected soon.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
